Exelixis, Inc. (Nasdaq: EXEL) announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE